Home / Reports / Rasonque (daraxonrasib)
Oncology

Rasonque (daraxonrasib) in Metastatic Pancreatic Cancer: market forecast and verdict

Revolution Medicines · FDA approved 26 August 2026 · EU positive opinion 15 October 2026

OUR VERDICTA practice changing second line therapy with a first line prize still to win.Large survival gains will drive fast uptake; skin, mouth and gut side effects and a short treatment course cap revenue per patient.
~USD 1.8B
Base case US net revenue, 2031, second line onlyRange USD 0.9B to 4.5B · Zaash Labs estimate
13.2 vs 6.7 mo
median overall survival vs chemotherapy (RASolute 302)
HR 0.40
a 60% lower risk of death vs chemotherapy
~67,000
people diagnosed with pancreatic cancer in the US each year

What was approved and why it matters

Revolution Medicines' Rasonque (daraxonrasib) is the first RAS(ON) inhibitor, a once daily pill for adults with metastatic pancreatic adenocarcinoma after prior systemic therapy. In the Phase III RASolute 302 trial it roughly doubled survival compared with chemotherapy.

Frequently asked questions

When was daraxonrasib approved?

The FDA approved Rasonque (daraxonrasib) on 26 August 2026 for previously treated metastatic pancreatic adenocarcinoma. The CHMP recommended EU approval on 15 October 2026.

What are daraxonrasib's projected sales?

Zaash Labs' base case is about USD 1.8 billion of US net revenue in 2031 from second line use alone. Approval in first line could lift that toward USD 4.5 billion.

What did RASolute 302 show?

Median overall survival was 13.2 months with daraxonrasib against 6.7 months with chemotherapy (hazard ratio 0.40), and median progression free survival 7.2 against 3.6 months.

Figures are company reported or from published sources unless marked as Zaash Labs estimates. Sources are listed in the executive summary and the full report. Market research to support business decisions; not investment advice.